▲ 12.28%
prev close
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+0
1 buys · 1 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2022-11-08 | KODKodiak Sciences Inc | Sell | $1,001 - $15,000 | 1207d ago | — | |
| 2022-07-18 | KODKodiak Sciences Inc | Buy | $1,001 - $15,000 | 1301d ago | — |
2022-11-08
Christopher L. Jacobs
KOD
Amount
$1,001 - $15,000
Filed
1207d ago
2022-07-18
Christopher L. Jacobs
KOD
Amount
$1,001 - $15,000
Filed
1301d ago
Recent News
Powered by Polygon.io
Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday
Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type
Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
Trade Timeline
Congressional activity, newest first
Christopher L. Jacobs
2022-11-08 · Sale
$1,001 - $15,000
Christopher L. Jacobs
2022-07-18 · Purchase
$1,001 - $15,000